A study on waste PCB fibres reinforced concrete with and without silica fume made from electronic waste.

This research goal is to appraise the effect of electronic waste on concrete properties by examining the mechanical properties of concrete reinforced with waste printed circuit boards (PCBs). PCB fibres, each 50 mm long, were mixed in varying proportions (1-5% by weight of cement). Silica fume (SF) was used as a 12% weight replacement for cement to conserve the properties of PCB fibre-reinforced concrete while tumbling cement consumption. Following a 28-day curing period, the fresh and hardened characteristics of PCB fibre-reinforced concrete were juxtaposed with those of conventional concrete. The experimental results led to the conclusion that 5% by weight of cement is the most effective proportion of PCB fibres to include in both PCB fibre-reinforced concrete and silica fume-modified PCB fibre-reinforced concrete. The addition of PCB fibres and silica fume significantly increased the mechanical strength of the concrete, making it suitable for high-strength concrete applications. Based on a similar investigational research design, an artificial neural network model was created, and it played a critical role in predicting the mechanical properties of the concrete. The model produced accurate results, with an R-squared (R2) value greater than 0.99.

A pilot study of HTLV-I infection in high-risk individuals & their family members from India.

BACKGROUND & OBJECTIVES: Human T lymphotropic virus-I (HTLV-I) has been associated with adult T cell lymphoma/leukemia (ATLL). There are Indian studies on HTLV-I infection among people with sexually transmitted infection, but no large study has been conducted on individuals with haematological malignancies. In this group of individuals, serology is known to under-diagnose HTLV-I infection. This study was carried out to identify serologically and where possible with molecular techniques, HTLV-I infection in individuals with haematological malignancies. To understand the modes of transmission, family members of individuals with proven HTLV-I infection were also studied. Individuals with sexually transmitted infection (STI), blood donors and pregnant women were also studied. METHODS: Particle agglutination test was used to detect antibody to HTLV-I. HTLV genome was amplified by polymerase chain reaction (PCR) and detected with probes by digoxiginin (Dig) ELISA. RESULTS: There was no serological evidence of HTLV-I infection among the healthy blood donors and pregnant women studied. High prevalence of anti-HTLV-I antibody was identified in the patients with haematological malignancies (8 of 86 patients, 9.3%) and a lower prevalence in individuals with STI (8 of 670 individuals, 1.2%). In the STI group, all 8 individuals seroreactive to HTLV-I were coinfected with human immunodeficiency virus (HIV). In the group with haematological malignancies, three of 22 (13.6%) patients with leukemia, 3 of 11 (27.3%) with cutaneous T-cell lymphoma (CTCL) and 2 of 53 (3.8%) with lymphoma were reactive for anti-HTLV-I antibody. In this group, PCR identified all the seroreactive individuals tested. There were also seronegative infected individuals who were only identified by PCR. There was also a large number of seronegative family members who were only positive by PCR. INTERPRETATION & CONCLUSION: The study revealed a strong disease association of HTLV-I with haematological malignancies and evidence for both horizontal and vertical transmission of the infection in the Indian population. HTLV-I infection appears to be common among family members of individuals with HTLV-I associated haematological malignancies.

Hospital-based evaluation of two rapid human immunodeficiency virus antibody screening tests.

Two rapid human immunodeficiency virus (HIV) screening assays, HIV TRI-DOT and HIV-SPOT were compared with standard enzyme-linked immunosorbent assays according to a testing algorithm. Sensitivities and specificities in the real-time evaluation were 99.5 and 99.9% for TRI-DOT and 98.2 and 99.7% for HIV-SPOT, respectively. These two tests are suitable for use where facilities and laboratory expertise are limited.